{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T04:39:31Z","timestamp":1781325571575,"version":"3.54.1"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/N020081\/1"],"award-info":[{"award-number":["MR\/N020081\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","award":["GA858070"],"award-info":[{"award-number":["GA858070"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.bcp.2023.116007","type":"journal-article","created":{"date-parts":[[2023,12,24]],"date-time":"2023-12-24T00:36:10Z","timestamp":1703378170000},"page":"116007","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Role of endothelin ETA receptors in the hypertension induced by the VEGFR-2 kinase inhibitors axitinib and lenvatinib in conscious freely-moving rats"],"prefix":"10.1016","volume":"228","author":[{"given":"Patrizia","family":"Pannucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke","family":"Van Daele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha L.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward S.","family":"Wragg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"March","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marleen","family":"Groenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4424-239X","authenticated-orcid":false,"given":"Stephen J.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette","family":"Woolard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2023.116007_b0005","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/er.2003-0027","article-title":"Vascular endothelial growth factor: basic science and clinical progress","volume":"25","author":"Ferrara","year":"2004","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bcp.2023.116007_b0010","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1684\/ecn.2009.0170","article-title":"VEGF-A: a critical regulator of blood vessel growth","volume":"20","author":"Ferrara","year":"2009","journal-title":"Eur. Cytokine Netw."},{"key":"10.1016\/j.bcp.2023.116007_b0015","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1177\/1947601911423031","article-title":"Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies","volume":"2","author":"Shibuya","year":"2011","journal-title":"Genes Cancer"},{"key":"10.1016\/j.bcp.2023.116007_b0020","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1161\/HYPERTENSIONAHA.117.08856","article-title":"Recent advances in hypertension and cardiovascular toxicities with vascular endothelial growth factor inhibition","volume":"70","author":"Touyz","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2023.116007_b0025","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.3390\/ijms19041264","article-title":"Molecular Pharmacology of VEGF-A Isoforms: Binding and Signalling at VEGFR2","volume":"19","author":"Peach","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2023.116007_b0030","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1042\/BJ20110301","article-title":"Signal transduction by vascular endothelial growth factor receptors","volume":"437","author":"Koch","year":"2011","journal-title":"Biochem. J."},{"key":"10.1016\/j.bcp.2023.116007_b0035","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/j.cellsig.2007.05.013","article-title":"Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition","volume":"19","author":"Holmes","year":"2007","journal-title":"Cell. Signal."},{"key":"10.1016\/j.bcp.2023.116007_b0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10456-009-9160-6","article-title":"Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?","volume":"13","author":"Gotink","year":"2010","journal-title":"Angiogenesis"},{"key":"10.1016\/j.bcp.2023.116007_b0045","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/nature04478","article-title":"Angiogenesis in life, disease and medicine","volume":"438","author":"Carmeliet","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2023.116007_b0050","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrd.2015.17","article-title":"Ten years of anti-vascular endothelial growth factor therapy","volume":"15","author":"Ferrara","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2023.116007_b0055","doi-asserted-by":"crossref","first-page":"10797","DOI":"10.1021\/jm301085w","article-title":"Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors","volume":"55","author":"Musumeci","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2023.116007_b0060","doi-asserted-by":"crossref","first-page":"7272","DOI":"10.1158\/1078-0432.CCR-08-0652","article-title":"Nonclinical anti-angiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3","volume":"14","author":"Hu-Lowe","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2023.116007_b0065","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s13318-017-0403-4","article-title":"Clinical Pharmacokinetic and Pharmacodynamic Profile of Lenvatinib, an Orally Active, Small-Molecule, Multitargeted Tyrosine Kinase Inhibitor","volume":"42","author":"Hussein","year":"2017","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.bcp.2023.116007_b0070","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1470-2045(07)70285-1","article-title":"Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study","volume":"8","author":"Rixe","year":"2007","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bcp.2023.116007_b0075","first-page":"333","article-title":"Axitinib: newly approved for renal cell carcinoma","volume":"3","author":"Tyler","year":"2012","journal-title":"J. Adv. Pract. Oncol."},{"key":"10.1016\/j.bcp.2023.116007_b0080","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nrclinonc.2015.30","article-title":"SELECT\u2014lenvatinib in thyroid cancer","volume":"12","author":"Killock","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bcp.2023.116007_b0085","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2023.116007_b0090","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ctrv.2015.11.003","article-title":"Lenvatinib: Role in thyroid cancer and other solid tumors","volume":"42","author":"Cabanillas","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bcp.2023.116007_b0095","doi-asserted-by":"crossref","first-page":"18281","DOI":"10.1073\/pnas.1207759109","article-title":"Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors","volume":"109","author":"McTigue","year":"2012","journal-title":"PNAS"},{"key":"10.1016\/j.bcp.2023.116007_b0100","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.1080\/07391102.2021.1872417","article-title":"Exploration of structural requirements for the inhibition of VEGFR-2 tyrosine kinase: Binding site analysis of type II, 'DFG-out' inhibitors","volume":"40","author":"Modi","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.bcp.2023.116007_b0105","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1021\/ml500394m","article-title":"Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization","volume":"6","author":"Okamoto","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2023.116007_b0110","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.phrs.2017.03.010","article-title":"Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas","volume":"120","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2023.116007_b0115","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1096\/fj.201600749R","article-title":"Effects of 4 multitargeted receptor tyrosine kinase inhibitors on regional hemodynamics in conscious, freely moving rats","volume":"31","author":"Carter","year":"2017","journal-title":"FASEB J."},{"key":"10.1016\/j.bcp.2023.116007_b0120","doi-asserted-by":"crossref","first-page":"e00477","DOI":"10.1002\/prp2.477","article-title":"Long-term cardiovascular effects of vandetanib and pazopanib in normotensive rats","volume":"7","author":"Cooper","year":"2019","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.bcp.2023.116007_b0125","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrclinonc.2009.94","article-title":"Adverse effects of anticancer agents that target the VEGF pathway","volume":"6","author":"Chen","year":"2009","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bcp.2023.116007_b0130","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/bph.14103","article-title":"Quantifying the relationship between inhibition of VEGF receptor 2, drug-induced blood pressure elevation and hypertension","volume":"175","author":"Collins","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2023.116007_b0135","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11523-014-0307-z","article-title":"Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial","volume":"10","author":"Rini","year":"2015","journal-title":"Target. Oncol."},{"key":"10.1016\/j.bcp.2023.116007_b0140","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.critrevonc.2014.06.003","article-title":"Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysis","volume":"92","author":"Abdel-Rahman","year":"2014","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.bcp.2023.116007_b0145","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1253\/circrep.CR-21-0008","article-title":"Axitinib Induces and Aggravates Hypertension Regardless of Prior Treatment With Tyrosine Kinase Inhibitors","volume":"3","author":"Kadowaki","year":"2021","journal-title":"Circ. Rep."},{"key":"10.1016\/j.bcp.2023.116007_b0150","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.3390\/ijms18081736","article-title":"Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma","volume":"18","author":"Bendtsen","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2023.116007_b0155","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S1470-2045(20)30162-5","article-title":"Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial","volume":"21","author":"Sato","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bcp.2023.116007_b0160","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1161\/HYPERTENSIONAHA.109.149690","article-title":"Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels","volume":"56","author":"Kappers","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2023.116007_b0165","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s11912-022-01224-0","article-title":"VEGF Receptor Inhibitor-Induced Hypertension: Emerging Mechanisms and Clinical Implications","volume":"24","author":"Camarda","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.bcp.2023.116007_b0170","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1161\/HYPERTENSIONAHA.111.173559","article-title":"The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system","volume":"58","author":"Kappers","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2023.116007_b0175","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1161\/HYPERTENSIONAHA.122.19079","article-title":"Effect of Sunitinib Treatment on Skin Sodium Accumulation in Patients With Renal Cancer: a Pilot Study","volume":"79","author":"Mark\u00f3","year":"2022","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2023.116007_b0180","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1124\/pr.115.011833","article-title":"Endothelin","volume":"68","author":"Davenport","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bcp.2023.116007_b0185","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/FJC.0b013e3181993493","article-title":"ETA receptor blockade with atrasentan prevents hypertension with the multitargeted tyrosine kinase inhibitor ABT-869 in telemetry-instrumented rats","volume":"53","author":"Banfor","year":"2009","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.bcp.2023.116007_b0190","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1161\/HYPERTENSIONAHA.114.04187","article-title":"Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib preclinical study","volume":"64","author":"Lankhorst","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2023.116007_b0195","first-page":"228","article-title":"Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist","volume":"270","author":"Clozel","year":"1994","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2008","key":"10.1016\/j.bcp.2023.116007_b0200","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/sj.bjp.0707516","article-title":"The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?","volume":"153","author":"Kirkby","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2023.116007_b0205","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1111\/j.1476-5381.2010.00872.x","article-title":"Animal research: Reporting in vivo experiments: The ARRIVE guidelines","volume":"160","author":"Kilkenny","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2023.116007_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115672","article-title":"Characterisation of tyrosine kinase inhibitor-receptor interactions at VEGFR2 using sunitinib-red and nanoBRET","volume":"214","author":"Van Daele","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2023.116007_b0215","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13045-016-0374-y","article-title":"New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy","volume":"10","author":"Zarrabi","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bcp.2023.116007_b0220","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm0195-27","article-title":"Angiogenesis in cancer, vascular, rheumatoid and other disease","volume":"1","author":"Folkman","year":"1995","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2023.116007_b0225","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMra1601333","article-title":"Systemic Therapy for Metastatic Renal-Cell Carcinoma","volume":"376","author":"Choueiri","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2023.116007_b0230","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1200\/JCO.2018.79.0253","article-title":"Evolving Systemic Treatment Landscape for Patients With Advanced Renal Cell Carcinoma","volume":"36","author":"McKay","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2023.116007_b0235","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.tcm.2012.09.008","article-title":"Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives","volume":"23","author":"Bair","year":"2013","journal-title":"Trends Cardiovasc. Med."},{"key":"10.1016\/j.bcp.2023.116007_b0240","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.cjca.2014.02.011","article-title":"Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome","volume":"30","author":"Small","year":"2014","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.bcp.2023.116007_b0245","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1093\/cvr\/cvz260","article-title":"Selective ETA vs. dual ETA\/B receptor blockade for the prevention of sunitinib-induced hypertension and albuminuria in WKY rats","volume":"116","author":"Mirabito Colafella","year":"2020","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.bcp.2023.116007_b0250","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1161\/HYPERTENSIONAHA.115.05435","article-title":"Greater sensitivity of blood pressure than renal toxicity to tyrosine kinase receptor inhibition with sunitinib","volume":"66","author":"Lankhorst","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2023.116007_b0255","article-title":"Blood volume in the rat","volume":"72\u20136","author":"Lee","year":"1985","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bcp.2023.116007_b0260","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2165\/00003088-200443150-00003","article-title":"Clinical pharmacology of bosentan, a dual endothelin receptor antagonist","volume":"43","author":"Dingemanse","year":"2004","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.bcp.2023.116007_b0265","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2125.2007.02979.x","article-title":"The pharmacokinetic profile of sitaxsentan, a selective endothelin receptor antagonist, in varying degrees of renal impairment","volume":"64","author":"Dhaun","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2023.116007_b0270","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s40265-022-01708-0","article-title":"Clazosentan: first approval","volume":"82","author":"Lee","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.bcp.2023.116007_b0275","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/s44161-023-00347-2","article-title":"Current and future strategies for targeting the enothelin pathway in cardiovascular disease","volume":"2","author":"Abraham","year":"2023","journal-title":"Nat. Cardiovasc. Res."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295223006007?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295223006007?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T05:14:33Z","timestamp":1731474873000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295223006007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":55,"alternative-id":["S0006295223006007"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2023.116007","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of endothelin ETA receptors in the hypertension induced by the VEGFR-2 kinase inhibitors axitinib and lenvatinib in conscious freely-moving rats","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2023.116007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116007"}}